image
Healthcare - Biotechnology - NASDAQ - US
$ 5.79
2.12 %
$ 24 M
Market Cap
3.43
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one TENX stock under the worst case scenario is HIDDEN Compared to the current market price of 5.79 USD, Tenax Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one TENX stock under the base case scenario is HIDDEN Compared to the current market price of 5.79 USD, Tenax Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one TENX stock under the best case scenario is HIDDEN Compared to the current market price of 5.79 USD, Tenax Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TENX

image
$8.0$8.0$7.5$7.5$7.0$7.0$6.5$6.5$6.0$6.0$5.5$5.5$5.0$5.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-19.5 M OPERATING INCOME
-136.75%
-17.6 M NET INCOME
-128.28%
-14.8 M OPERATING CASH FLOW
-150.88%
0 INVESTING CASH FLOW
0.00%
99.9 M FINANCING CASH FLOW
636.01%
0 REVENUE
0.00%
0 OPERATING INCOME
0.00%
-10.4 M NET INCOME
-66.08%
-6.97 M OPERATING CASH FLOW
-97.53%
0 INVESTING CASH FLOW
0.00%
23.6 M FINANCING CASH FLOW
34940.52%
Balance Sheet Tenax Therapeutics, Inc.
image
Current Assets 96.7 M
Cash & Short-Term Investments 94.9 M
Receivables 0
Other Current Assets 1.84 M
Non-Current Assets 0
Long-Term Investments 0
PP&E 0
Other Non-Current Assets 0
98.10 %Total Assets$96.7m
Current Liabilities 4.69 M
Accounts Payable 3.16 M
Short-Term Debt 0
Other Current Liabilities 1.54 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
67.27 %32.73 %Total Liabilities$4.7m
EFFICIENCY
Earnings Waterfall Tenax Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 19.5 M
Operating Income -19.5 M
Other Expenses -1.89 M
Net Income -17.6 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)(18m)(18m)(20m)(20m)000(19m)(19m)2m(18m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-19.13% ROE
-19.13%
-18.21% ROA
-18.21%
-21.19% ROIC
-21.19%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Tenax Therapeutics, Inc.
image
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -17.6 M
Depreciation & Amortization 46 K
Capital Expenditures 0
Stock-Based Compensation 1.12 M
Change in Working Capital 1.64 M
Others 546 K
Free Cash Flow -14.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Tenax Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for TENX of $17.5 , with forecasts ranging from a low of $15 to a high of $20 .
TENX Lowest Price Target Wall Street Target
15 USD 159.07%
TENX Average Price Target Wall Street Target
17.5 USD 202.25%
TENX Highest Price Target Wall Street Target
20 USD 245.42%
Price
Max Price Target
Min Price Target
Average Price Target
20201818161614141212101088664422Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership Tenax Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
201 K USD 2
9-12 MONTHS
7. News
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026 globenewswire.com - 1 month ago
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts Tenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-modifying therapy for PH-HFpEF, with prior phase 2 success in improving exercise capacity. The company raised $25 million in March 2025, ensuring sufficient funding through 2027 to meet clinical milestones. seekingalpha.com - 2 months ago
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025. globenewswire.com - 3 months ago
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027 globenewswire.com - 3 months ago
Tenax Therapeutics Announces $25 Million Private Placement CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private placement expenses. globenewswire.com - 3 months ago
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025 globenewswire.com - 3 months ago
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference, which is taking place from March 10-12, 2025, in Miami, FL. globenewswire.com - 4 months ago
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference CHAPEL HILL, N.C., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference, which is taking place from February 5-6, 2025, in New York, NY. globenewswire.com - 5 months ago
Tenax Therapeutics, Inc. (TENX) Guggenheim Healthcare Innovation Conference (Transcript) Tenax Therapeutics, Inc. (NASDAQ:TENX ) Guggenheim Healthcare Innovation Conference November 13, 2024 1:00 PM ET Company Participants Chris Giordano - President and CEO Stuart Rich - Chief Medical Officer Conference Call Participants Seamus Fernandez - Guggenheim Securities Seamus Fernandez Good afternoon, everybody. And welcome again to Guggenheim Securities Inaugural Healthcare Innovation Conference. seekingalpha.com - 7 months ago
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update Raised Gross Proceeds of Approximately $100 Million in a Private Placement with Leading Institutional Healthcare Investors globenewswire.com - 7 months ago
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference CHAPEL HILL, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the Guggenheim Healthcare Innovation Conference in Boston, Massachusetts, from November 11-13, 2024. Tenax's CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a session investors can attend live or via webcast. globenewswire.com - 8 months ago
Why Is Tenax Therapeutics (TENX) Stock Up 29% Today? Tenax Therapeutics (NASDAQ: TENX ) stock is soaring higher on Tuesday after the company announced the completion of an oversubscribed private placement for its shares. This oversubscribed private placement has Tenax Therapeutics expecting $100 million in gross proceeds. investorplace.com - 10 months ago
8. Profile Summary

Tenax Therapeutics, Inc. TENX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 24 M
Dividend Yield 0.00%
Description Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
Contact ONE Copley Parkway, Chapel Hill, NC, 27560 https://www.tenaxthera.com
IPO Date April 4, 1994
Employees 4
Officers Mr. Thomas A. McGauley Interim Chief Financial Officer and Principal Financial Officer & Principal Accounting Officer Dr. Stuart Rich M.D. Chief Medical Officer & Director Dr. Douglas Hay Ph.D. Executive Vice President of Regulatory Affairs Mr. Christopher T. Giordano Chief Executive Officer, President & Director Mr. Doug Randall Chief Business Officer